Öz
The objective of this study was to evaluate the
mechanical properties of transdermal therapeutic
systems (TTS) containing captopril together with
synthetic and pH independent polymers, Eudragit
RL 100 and RS 100. The formulations were
characterized in terms of their adhesiveness and
bioadhesiveness by using texture analyser. These
optimum formulations were chosen according to the
results of our previous study regarding in vitro
dissolution and ex vivo diffusion rate studies through
excised human skin by using Franz Diffusion Cell.
Results indicated that the mechanical properties of
the formulations were suitable to be used as a
transdermal patch.
Keywords: captopril, transdermal therapeutic
system, patch adhesiveness, patch bioadhesiveness,
texture analyser
Anahtar Kelimeler
captopril transdermal therapeutic system patch adhesiveness patch bioadhesiveness texture analyser
Kaynakça
- Bhattacharya ML, Alper S. Pharmacology of Volume Regulation. In: Principles of Pharmacology. Editor: Golan DE, Lippincott, Williams & Wilkins. China. 2008: 345-65.
- Benowitz NL. Cardiovascular and Renal Drugs, Antihipertensive Agents. In: Basic and Clinical Pharmacology. Editor: Katzung BG, McGraw- Hill Co. USA. 2007: 159-83.
- European Pharmacopoeia. Council of Europe. Strasbourg. 2007: 737-38.
- Ferguson RK, Brunner HR, Turini GA, Gavras H, McKinstry DN. A specific orally active inhibitor of angiotensin- converting enzyme in man. Lancet 1977;1:775-8.
- Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin converting enzyme: new class of orally active antihypertensive agents. Science 1977;196:441-4.
- Huang Y, Tsai Y, Chang J, Liu JC, Tsai M J, Wu P. Effect of antioxidants and anti-irritants on the stability, skin irritation and penetration capacity of captopril gel. Int J Pharm 2002;241:345-51.
- Gavras H, Brunner HR, Turini GA, Kershaw GR, Tifft CP, Guttelod S, Gavras I, Vukovish RA, McKinstry DN. Antihypertensive effect of the oral angiotensin converting enzyme inhibitor SQ 14, 225 in man. New Engl J Med 1978;298:991-5.
- Bravo EL, Tarazi RC. Converting enzyme inhibition with an orally active compound in hypertensive man. Hypertension 1979;1:39-46.
- Brunner HR, Gavras H, Waebar B, Kershaw GR, Turini GA, Vukovish RA, McKinstry DN. Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med 1979;90:19-23.
- Testa MA, Anderson RB, Nackley JF, Hollenberg NK, and the quality-of-life hypertension study group. Quality of life and antihypertensive therapy in men: a comparison of captopril with enalapril. New Engl J Med 1993;328:907-13.
- Seta Y, Higuchi F, Kawahara Y, Nishimura K, Okada R. Design and preparation of captopril sustained release dosage forms and their biopharmaceutical properties. Int J Pharm 1988;41:245-54
- Anaizi NH, Swenson C. Instability of captopril solution. Am J Hosp Pharm 1993;50:486-8.
- Duchin KL, Singhvi SM, Willard DA, Migdalof BH, McKinstry DN. Captopril kinetics. Clin Pharmacol Ther 1982;31: 452-8.
Öz
Kaynakça
- Bhattacharya ML, Alper S. Pharmacology of Volume Regulation. In: Principles of Pharmacology. Editor: Golan DE, Lippincott, Williams & Wilkins. China. 2008: 345-65.
- Benowitz NL. Cardiovascular and Renal Drugs, Antihipertensive Agents. In: Basic and Clinical Pharmacology. Editor: Katzung BG, McGraw- Hill Co. USA. 2007: 159-83.
- European Pharmacopoeia. Council of Europe. Strasbourg. 2007: 737-38.
- Ferguson RK, Brunner HR, Turini GA, Gavras H, McKinstry DN. A specific orally active inhibitor of angiotensin- converting enzyme in man. Lancet 1977;1:775-8.
- Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin converting enzyme: new class of orally active antihypertensive agents. Science 1977;196:441-4.
- Huang Y, Tsai Y, Chang J, Liu JC, Tsai M J, Wu P. Effect of antioxidants and anti-irritants on the stability, skin irritation and penetration capacity of captopril gel. Int J Pharm 2002;241:345-51.
- Gavras H, Brunner HR, Turini GA, Kershaw GR, Tifft CP, Guttelod S, Gavras I, Vukovish RA, McKinstry DN. Antihypertensive effect of the oral angiotensin converting enzyme inhibitor SQ 14, 225 in man. New Engl J Med 1978;298:991-5.
- Bravo EL, Tarazi RC. Converting enzyme inhibition with an orally active compound in hypertensive man. Hypertension 1979;1:39-46.
- Brunner HR, Gavras H, Waebar B, Kershaw GR, Turini GA, Vukovish RA, McKinstry DN. Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med 1979;90:19-23.
- Testa MA, Anderson RB, Nackley JF, Hollenberg NK, and the quality-of-life hypertension study group. Quality of life and antihypertensive therapy in men: a comparison of captopril with enalapril. New Engl J Med 1993;328:907-13.
- Seta Y, Higuchi F, Kawahara Y, Nishimura K, Okada R. Design and preparation of captopril sustained release dosage forms and their biopharmaceutical properties. Int J Pharm 1988;41:245-54
- Anaizi NH, Swenson C. Instability of captopril solution. Am J Hosp Pharm 1993;50:486-8.
- Duchin KL, Singhvi SM, Willard DA, Migdalof BH, McKinstry DN. Captopril kinetics. Clin Pharmacol Ther 1982;31: 452-8.
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Bölüm | Makaleler |
| Yazarlar | |
| Yayımlanma Tarihi | 7 Ocak 2015 |
| Yayımlandığı Sayı | Yıl 2015 Cilt: 19 Sayı: 1 |
Kaynak Göster
.